0000950170-24-095094.txt : 20240812 0000950170-24-095094.hdr.sgml : 20240812 20240812090003 ACCESSION NUMBER: 0000950170-24-095094 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240806 FILED AS OF DATE: 20240812 DATE AS OF CHANGE: 20240812 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HUNT RONALD CENTRAL INDEX KEY: 0001247851 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38503 FILM NUMBER: 241195096 MAIL ADDRESS: STREET 1: C/O CREDIT SUISSE 1ST BOSTON PRV EQY STREET 2: 11 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Iterum Therapeutics plc CENTRAL INDEX KEY: 0001659323 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: FITZWILLIAM COURT, 1ST FLOOR STREET 2: LEESON CLOSE CITY: DUBLIN 2 STATE: L2 ZIP: D02 YW24 BUSINESS PHONE: (872) 225-6077 MAIL ADDRESS: STREET 1: FITZWILLIAM COURT, 1ST FLOOR STREET 2: LEESON CLOSE CITY: DUBLIN 2 STATE: L2 ZIP: D02 YW24 FORMER COMPANY: FORMER CONFORMED NAME: Iterum Therapeutics Ltd DATE OF NAME CHANGE: 20151124 4 1 ownership.xml 4 X0508 4 2024-08-06 0001659323 Iterum Therapeutics plc ITRM 0001247851 HUNT RONALD C/O ITERUM THERAPEUTICS PLC FITZWILLIAM COURT, FL. 1, LEESON CLOSE DUBLIN 2 L2 IRELAND true false false false false Ordinary Shares 2024-08-06 4 M false 182453 A 253898 I By New Leaf Ventures III, L.P. Ordinary Shares 2024-08-06 4 M false 65481 A 91122 I By New Leaf Biopharma Opportunities II, L.P. Subscription Rights (right to buy) 0.61 2024-08-06 4 M false 364906 0 D 2024-07-22 2024-08-06 Units 0 I By New Leaf Ventures III, L.P. Warrants (right to buy) 1.21 2024-08-06 4 M false 182453 A 2024-08-09 2025-08-09 Ordinary Shares 91226 182453 I By New Leaf Ventures III, L.P. Warrants (right to buy) 1.21 2024-08-06 4 M false 182453 A 2024-08-09 2029-08-09 Ordinary Shares 182453 182453 I By New Leaf Ventures III, L.P. Subscription Rights (right to buy) 0.61 2024-08-06 4 M false 130962 0 D 2024-07-22 2024-08-06 Units 0 I By New Leaf Biopharma Opportunities II, L.P. Warrants (right to buy) 1.21 2024-08-06 4 M false 65481 A 2024-08-09 2025-08-09 Ordinary Shares 32740 65481 I By New Leaf Biopharma Opportunities II, L.P. Warrants (right to buy) 1.21 2024-08-06 4 M false 65481 A 2024-08-09 2029-08-09 Ordinary Shares 65481 65481 I By New Leaf Biopharma Opportunities II, L.P. The reported securities were purchased in the Issuer's rights offering (the "Offering") which closed on August 9, 2024. As part of the Offering, New Leaf Ventures III, L.P. ("NLV-III") purchased 182,453 units at a subscription price of $1.21 per whole unit. Each unit consisted of (a) one ordinary share, (b) a warrant to purchase 0.50 ordinary shares, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance ("1-year warrants"), and (c) a warrant to purchase one ordinary share, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance ("5-year warrants"). These shares are held directly by NLV-III. New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NLVM-III LLC and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The reporting person disclaims Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of his pecuniary interest therein, if any. The reported securities were purchased in the Issuer's rights offering (the "Offering") which closed on August 9, 2024. As part of the Offering, New Leaf Biopharma Opportunities II, L.P. ("NBPO-II") purchased 65,481 units at a subscription price of $1.21 per whole unit. Each unit consisted of (a) one ordinary share, (b) a warrant to purchase 0.50 ordinary shares, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance ("1-year warrants"), and (c) a warrant to purchase one ordinary share, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance ("5-year warrants"). These shares are held directly by NBPO-II. New Leaf BPO Associates II, L.P. ("NBPO-IIA") is the general partner of NBPO-II and New Leaf BPO Management II, L.L.C. ("NBPO-IIM") is the general partner of NBPO-IIA, and each of NBPO-IIA and NBPO-IIM may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NBPO-II. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NBPO-IIM and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NBPO-II. The reporting person disclaims Section 16 beneficial ownership of the securities held by NBPO-II, except to the extent of his pecuniary interest therein, if any. NLV-III validly exercised 364,906 subscription rights to acquire 182,453 units composed of (i) 182,453 ordinary shares, (ii) 182,453 1-year warrants and (iii) 182,453 5-year warrants. NBPO-II validly exercised 130,962 subscription rights to acquire 65,481 units composed of (i) 65,481 ordinary shares, (ii) 65,481 1-year warrants and (iii) 65,481 5-year warrants. /s/ Ronald M. Hunt 2024-08-12